[ACAD] ACADIA Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 29.75 Change: 2.08 (7.52%)
Ext. hours: 29.65 Change: -0.1 (-0.34%)

chart ACAD

Refresh chart

Strongest Trends Summary For ACAD

ACAD is in the long-term up 988% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Fundamental Ratios
Shares Outstanding EPS-2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -85.71% Sales Growth - Q/Q-91.67% P/E-10.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.09% ROE-40.35% ROI
Current Ratio18.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-123217% Net Profit Margin-122364% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.44 M Cash From Investing Activities38.47 M Cash From Operating Activities-25.35 M Gross Profit
Net Profit-40.38 M Operating Profit-40.55 M Total Assets301.96 M Total Current Assets299.9 M
Total Current Liabilities16.65 M Total Debt Total Liabilities16.87 M Total Revenue
Technical Data
High 52 week39.14 Low 52 week15.12 Last close17.87 Last change1.53%
RSI52.92 Average true range0.66 Beta1.75 Volume3.38 M
Simple moving average 20 days0.08% Simple moving average 50 days-2.47% Simple moving average 200 days-35.73%
Performance Data
Performance Week2.47% Performance Month-2.14% Performance Quart-30.98% Performance Half-40.61%
Performance Year-34.78% Performance Year-to-date-40.65% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.94% Volatility yearly30.98% Relative Volume1230.89% Average Volume2.95 M
New High New Low

News

2019-06-13 08:02:53 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-06-11 20:23:24 | Is ACADIA Pharmaceuticals Inc. ACAD A Good Stock To Buy?

2019-06-11 08:03:44 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-06-11 06:59:38 | When Will ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Turn A Profit?

2019-06-10 08:02:57 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-06-06 08:02:52 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-06-04 09:00:00 | ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

2019-06-04 08:02:55 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-05-18 11:00:00 | ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting

2019-05-08 15:30:00 | Why Acadia Pharmaceuticals Stock Slumped in April

2019-05-07 09:00:00 | ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

2019-05-07 08:05:40 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-05-02 03:24:18 | Acadia Pharmaceuticals ACAD Q1 2019 Earnings Call Transcript

2019-05-02 01:20:53 | Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT

2019-05-01 19:35:11 | Acadia Pharmaceuticals ACAD Reports Q1 Loss, Tops Revenue Estimates

2019-05-01 18:29:19 | Acadia: 1Q Earnings Snapshot

2019-05-01 16:05:00 | ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-04-30 08:03:55 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-04-29 21:58:12 | Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. ACAD?

2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure

2019-04-25 09:00:00 | ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

2019-04-24 10:33:02 | Analysts Estimate Acadia Pharmaceuticals ACAD to Report a Decline in Earnings: What to Look Out for

2019-04-19 09:11:16 | Should ACADIA Pharmaceuticals NASDAQ:ACAD Be Disappointed With Their -30% Profit?

2019-04-17 09:00:00 | ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019

2019-04-11 09:00:00 | ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country

2019-04-09 10:45:45 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-04-02 09:00:00 | ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019

2019-04-01 09:00:00 | ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer

2019-03-29 07:20:00 | Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

2019-03-28 07:54:59 | The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

2019-03-27 16:10:00 | Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology

2019-03-26 08:22:11 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-13 13:18:04 | Is ACADIA Pharmaceuticals Inc.’s NASDAQ:ACAD Liquidity Good Enough?

2019-03-05 14:36:00 | Why Acadia Pharmaceuticals Stock Perked Up in February

2019-03-04 09:00:00 | ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019

2019-02-27 20:21:28 | Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT

2019-02-27 09:30:00 | 3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

2019-02-27 01:05:40 | Acadia Pharmaceuticals Inc ACAD Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-26 13:28:31 | Big Pharma faces the Senate in drug price hearings

2019-02-21 09:00:00 | ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

2019-02-15 16:08:09 | What's in the Cards for Bausch Health BHC Q4 Earnings?

2019-02-14 12:58:05 | 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

2019-02-13 08:15:00 | New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

2019-02-12 09:00:00 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019

2019-02-11 16:51:09 | Zoetis ZTS to Report Q4 Earnings: What's in the Cards?

2019-02-11 15:58:08 | Is a Disappointment in Store for Incyte INCY Q4 Earnings?

2019-02-08 16:56:09 | Tilray TLRY to Report Q4 Earnings: What's in the Cards?

2019-02-08 08:07:05 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.